SG Americas Securities LLC Buys Shares of 5,875 AnaptysBio, Inc. (NASDAQ:ANAB)

SG Americas Securities LLC bought a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 5,875 shares of the biotechnology company’s stock, valued at approximately $126,000.

A number of other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. increased its position in AnaptysBio by 2.1% during the 1st quarter. BlackRock Inc. now owns 1,895,494 shares of the biotechnology company’s stock valued at $41,246,000 after purchasing an additional 39,228 shares during the period. Vanguard Group Inc. increased its position in AnaptysBio by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,745,108 shares of the biotechnology company’s stock valued at $44,518,000 after purchasing an additional 14,638 shares during the period. State Street Corp increased its position in AnaptysBio by 10.0% during the 3rd quarter. State Street Corp now owns 1,271,727 shares of the biotechnology company’s stock valued at $32,442,000 after purchasing an additional 115,846 shares during the period. Woodline Partners LP grew its position in shares of AnaptysBio by 125.1% in the 2nd quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company’s stock worth $21,043,000 after buying an additional 574,987 shares during the last quarter. Finally, Braidwell LP grew its position in shares of AnaptysBio by 34.0% in the 1st quarter. Braidwell LP now owns 973,073 shares of the biotechnology company’s stock worth $21,174,000 after buying an additional 246,951 shares during the last quarter.

AnaptysBio Trading Up 0.6 %

NASDAQ:ANAB opened at $21.47 on Thursday. The company has a market cap of $574.54 million, a PE ratio of -3.53 and a beta of -0.30. AnaptysBio, Inc. has a twelve month low of $13.36 and a twelve month high of $27.50. The company’s 50 day moving average is $23.38 and its two-hundred day moving average is $20.55.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.74) by $0.15. The company had revenue of $9.01 million for the quarter, compared to the consensus estimate of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. As a group, analysts expect that AnaptysBio, Inc. will post -6.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the sale, the chief executive officer now owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of AnaptysBio stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the sale, the chief executive officer now directly owns 749,087 shares in the company, valued at approximately $16,045,443.54. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Dennis Mulroy sold 3,065 shares of AnaptysBio stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $23.63, for a total transaction of $72,425.95. Following the sale, the chief financial officer now owns 964 shares of the company’s stock, valued at $22,779.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 157,005 shares of company stock valued at $3,586,199. Insiders own 35.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ANAB has been the topic of a number of analyst reports. BTIG Research initiated coverage on shares of AnaptysBio in a research report on Monday, February 26th. They issued a “buy” rating and a $55.00 price objective on the stock. SVB Leerink initiated coverage on shares of AnaptysBio in a research report on Tuesday. They issued an “outperform” rating and a $47.00 price objective on the stock. JPMorgan Chase & Co. cut their price objective on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, April 1st. Piper Sandler initiated coverage on shares of AnaptysBio in a research report on Friday, February 16th. They issued an “overweight” rating and a $80.00 price objective on the stock. Finally, Wells Fargo & Company initiated coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They issued an “overweight” rating and a $56.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.22.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.